News & Updates

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021 by

Early administration (ie, pre-intubation/noninvasive ventilation) of the interleukin-6 receptor blocker tocilizumab in patients with severe COVID-19 led to more favourable outcomes compared with late administration (ie, post-intubation/noninvasive ventilation), according to data presented at ATS 2021.

Tocilizumab administration for severe COVID-19: Timing matters

09 Jun 2021

MetS may develop in people living with HIV on combination ART

09 Jun 2021 by

People living with HIV (PLHIV) who had ever taken combination antiretroviral therapy (cART) may be at a higher risk of metabolic syndrome (MetS), according to a recent Singapore study.

MetS may develop in people living with HIV on combination ART

09 Jun 2021

COVID-19 patients at risk of sequelae after acute phase of SARS-CoV-2 infection

08 Jun 2021 by

Patients with COVID-19 appear to have an increased risk of developing new clinical sequelae after the acute phase of SARS-CoV-2 infection, including specific types of sequelae less commonly seen in other viral illnesses, a study has found.

COVID-19 patients at risk of sequelae after acute phase of SARS-CoV-2 infection

08 Jun 2021

Urine, serum markers may help predict COVID-19 outcomes

06 Jun 2021

Urinary and serum biomarkers may help the early detection of acute kidney injury (AKI) in patients with COVID-19, signalling renal involvement and the potential need for greater medical attention, a recent study has found.

Urine, serum markers may help predict COVID-19 outcomes

06 Jun 2021

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021 by

While the rate of breakthrough infections is low among people who have been fully vaccinated against COVID-19, researchers found that older age and having anaemia were associated with an increased risk of such infections.

Breakthrough infections after COVID-19 vaccines: Who is at risk?

05 Jun 2021

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

04 Jun 2021

Long-term use of peginterferon therapy appears to induce sustained virologic response in about half of patients with hepatitis D virus infection, along with functional cure in some patients, as reported in a study.

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

04 Jun 2021

Current smokers more likely to experience COVID-19 symptoms

03 Jun 2021 by

Individuals who are smokers are more likely to report the classic symptoms suggestive of COVID-19 (fever, new persistent cough, and breathlessness) and have a greater symptom burden than non-smokers, a prospective UK-based study found.

Current smokers more likely to experience COVID-19 symptoms

03 Jun 2021

T-cell hyporeactivity foreshadows poor COVID-19 outcomes

03 Jun 2021

Hyporeactivity of the T-cell response seems to signal longer virus persistence and poor outcomes in patients with the novel coronavirus disease (COVID-19), a recent study has found.

T-cell hyporeactivity foreshadows poor COVID-19 outcomes

03 Jun 2021

C. difficile infection may lead to irritable bowel syndrome for some patients

03 Jun 2021

About 20 percent of patients develop postinfection irritable bowel syndrome after Clostridioides difficile infection, according to a study.

C. difficile infection may lead to irritable bowel syndrome for some patients

03 Jun 2021

4-month rifapentine regimen on par with 6-month standard TB care

02 Jun 2021 by

A shorter treatment course of 4 months with a rifapentine-based regimen containing moxifloxacin proves to be noninferior to a standard 6-month regimen in patients with drug-susceptible tuberculosis, a phase III randomized trial has shown.

4-month rifapentine regimen on par with 6-month standard TB care

02 Jun 2021

News & Updates

Filter by Specialty:

Specialty:

Tocilizumab administration for severe COVID-19: Timing matters

Tocilizumab administration for severe COVID-19: Timing matters

MetS may develop in people living with HIV on combination ART

MetS may develop in people living with HIV on combination ART

COVID-19 patients at risk of sequelae after acute phase of SARS-CoV-2 infection

COVID-19 patients at risk of sequelae after acute phase of SARS-CoV-2 infection

Urine, serum markers may help predict COVID-19 outcomes

Urine, serum markers may help predict COVID-19 outcomes

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Breakthrough infections after COVID-19 vaccines: Who is at risk?

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

Current smokers more likely to experience COVID-19 symptoms

Current smokers more likely to experience COVID-19 symptoms

T-cell hyporeactivity foreshadows poor COVID-19 outcomes

T-cell hyporeactivity foreshadows poor COVID-19 outcomes

C. difficile infection may lead to irritable bowel syndrome for some patients

C. difficile infection may lead to irritable bowel syndrome for some patients

4-month rifapentine regimen on par with 6-month standard TB care

4-month rifapentine regimen on par with 6-month standard TB care